Previous close | 0.6000 |
Open | 0.6000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 5.00 |
Expiry date | 2024-11-15 |
Day's range | 0.6000 - 0.6000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, announced today a strategic partnership with City
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Q1 2024 Cellectar Biosciences Inc Earnings Call